News for Sage Therapeutics, Inc. (SAGE)

Collaboration Revenue: $13.8 million in the first quarter of 2025, a 21% increase from the fourth quarter of 2024.R&D Expenses: $22.8 million in Q1 2025, a 68%

The following slide deck was published by Sage Therapeutics, Inc.

Sage Therapeutics reported strong Q1 2025 growth, with ZURZUVAE leading the charge in postpartum depression treatment.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call April 29, 2025 4:30 PM ETCompany ParticipantsAshley Kaplowitz - Investor RelationsBarry Greene -...

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. ”œWe delivered s

Revenue: Achieved $13.8 million in collaboration revenue from ZURZUVAE, slightly below the estimated $14.06 million.Earnings Per Share (EPS): Not provided, but

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -2.02% and 0.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireNEW YORK, April 22, 2025 NEW YORK, April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether c

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics, Inc. (NASDAQ: SAGE) today announced that it will host a live webcast on Tuesday, April 29, 2025, at 4:30 p.m. ET to review first quarter 202

Sage Therapeutics (SAGE) will announce its Q1 2025 financial results on April 29, 2025. A live webcast will be held at 4:30 p.m. ET, accessible via the

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sage Therapeutics, Inc. ( SAGE) (”œSage”) on behalf of

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click here to read my most recent analysis on SAGE.

U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming to boost U.S. manufacturing and reduce reliance on global suppliers, new auto tariffs were introduced on Wednesday, which will go into effect from April 3.

U.S. stock futures were mixed this morning, with the S&P 500 futures gaining around 0.1% on Tuesday. Shares of KB Home KBH fell sharply in today's pre-market t...

Sage Therapeutics (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) recent buyout effort. Read more here.

Significant Transaction by FMR LLC (Trades, Portfolio) On February 28, 2025, FMR LLC (Trades, Portfolio) executed a notable reduction in its holdings of Sage Th

On February 28, 2025, Morgan Stanley made a significant move by reducing its stake in Sage Therapeutics Inc (SAGE). The firm decreased its holdings by 3,582,018